Four pharmaceutical companies on Thursday announced investments in Mexico of more than 12 billion pesos (US $641.45 million).

The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer ...

(Reuters) -Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...

Meanwhile, drugmakers ramp up U.S. manufacturing investments to navigate policy shifts and protect supply chain resilience.

Trump demands U.S. drug prices match lowest international rates for some or face executive action. This article originally ...

Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...